IL17A and chronic rhinosinusitis with nasal polyps: In this limited case series, we report two CRSwNP patients who previously had failed treatment with an anti‐IL‐4/IL‐13 antibody (dupilumab) but showed favorable outcome with an anti‐IL‐17A antibody (secukinumab).